

Media Release

Zug, 1 June 2018

## **Publication of Annual Report 2017/2018 and Invitation to the Ordinary Shareholders' Meeting**

The invitation to the 17<sup>th</sup> Ordinary Shareholders' Meeting on 25 June 2018 has been sent to the shareholders today.

The detailed invitation with all motions of the Board of Directors is enclosed and displayed on the Company's website <http://www.hbmhealthcare.com>.

### Agenda for the 17<sup>th</sup> Ordinary Shareholders' Meeting on 25 June 2018

1. Statutory financial statements and group financial statements 2017/2018; reports of the auditors
2. Discharge from liability of the members of the Board of Directors and Management
3. Appropriation of results
  - Appropriation of disposable profit of CHF 136'370'716
  - Withholding tax-exempt cash distribution from the reserve from capital brought in of CHF 5.50 per entitled share
4. Elections regarding the Board of Directors
  - Re-elections of the Chairman and of the Members of the Board of Directors
  - Re-election of the members of the Compensation Committee
5. Compensation to the Board of Directors and to the Management
6. Appointment of auditors
7. Appointment of independent proxy-holder
8. Reduction of share capital by means of cancellation of own shares
9. Reduction of par value and additional distribution
  - Nominal value reduction of CHF 30.-- per share in favour of reserve from capital brought in
  - Withholding tax-exempt additional cash distribution from the reserve from capital brought in of CHF 1.50 per entitled share
10. Miscellaneous

HBM Healthcare Investments also published today its Annual Report 2017/2018 on the Company's website <http://www.hbmhealthcare.com/en/investors/financial-reports>

## Contact

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at [andreas.wicki@hbmhealthcare.com](mailto:andreas.wicki@hbmhealthcare.com)

## About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

## Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.